Title: Rationale of using common antifibrotic therapy in post Covid-19 fibrosis

Abstract:

Pulmonary fibrosis can occur in the absence of any  clear-cut inciting agent & cause, that happened in IPF  but it is more commonly devlope following acute and/or persistent lung injury/damage due to many causes such as : Connective tissue disorders Chronic granulomatous diseases, Medications, and  different respiratory infections ( Virals & fungals). Available clinical, radiographic, and autopsy data has indicated that pulmonary fibrosis is central to severe acute respiratory distress syndrome (SARS) and MERS pathology, and current evidence suggests that pulmonary fibrosis could also complicate infection by SARS-CoV-2. Various mechanisms of lung injury in COVID-19 have been described, with both viral and immune-mediated mechanisms being implicated. Apart from these, additional factors could predispose individuals to severe lung injury and lead to an increased risk of mortality or pulmonary fibrosis in survivors. Currently, there are no approved therapies for SARS COV2. Trials are based on drugs that are already approved for other diseases, have acceptable safety profiles or have been effective in animal studies against the other two highly pathogenic coronaviruses. Apart from the potent use of antivirals to reduce the viral effects, the use of antifibrotic therapies could also be under consideration based on the pulmonary fibrotic disease observed after COVID-19 recovery Pirfenidone and Nintedanib   are the two approved antifibrotic drugs for IPF.  Despite having different modes of action, are both effective in attenuating the rate of lung function decline and are widely considered to improve life expectancy.

Biography:

SM Abdullah Al Mamun, MBBS, MD, FCCP, Senior Consultant & coordinator of Respiratory Medicine At Evercare Hospitals Dhaka,  completed his graduation (MBBS) from Dhaka Medical College in 1994. In 1996, he started his Carrier as a research fellow in Bangladesh medical Research Council. In 1997, Dr. Mamun joined the Bangladesh health service after passing the BCS examination and in the same year enrolled in MD (Respiratory Medicine) course. In January 2000, he passed MCPS (Medicine from BCPS and in January 2003, he obtained MD degree in Respiratory Medicine from the National institute of Diseases of the chest and hospital Dhaka.  He attended many international seminars in Respiratory Medicine and presented many scientific papers in home and abroad. In 2006, he honored with FCCP from American college of chest physician. In 2009, he honored with APSR award and went for short fellowship (2 month) in Respiratory and critical Medicine in National university Hospital Singapore. In the same year he has been elected as International Regents of ACCP (American college of Chest physician) from Bangladesh for 3 years and visited USA, sponsored by ACCP and received training in Fibro optic Bronchoscopy. He also attended two training programs during European respiratory society Congress in Barcelona and Vienna in 2009 and 2010. In 2010, Dr. Mamun promoted in Govt. service as Assistant professor of Respiratory Medicine and joined to Sher-e Bangla Medical College Barisal. In August 2012, Dr. SM Abdullah Al Mamun joined the Board Review course of American college of Chest Physician in Phoenix, Arizona. Very soon in August2013, Mamun has been elected as Global Governor of ACCP from Bangladesh for next 3 years and after than he has been participating as faculty in different Chest congress.  Dr. Mamun is expert in Fiberoptic bronchoscopy and Lung function test. He performed more than 4500 fiberoptic bronchoscopy within last 12 years in home and abroad. His main focus of research activity is towards bronchial Asthma. His book on Bronchial Asthma has been published from Germany. Before joining Evercare Hospital Dhaka, he was working in Sher- E- Bangla Medical College Barisal as Assistant professor of respiratory Medicine.